KALA Stock Forecast: Kala Bio, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kala Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (71): Sales and profits are climbing, and climbing faster than before.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KALA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KALA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 Sept 2025 | Mizuho | Initiates | Outperform | — |
| 11 July 2025 | Ladenburg Thalmann | Initiates | Buy | — |
| 2 June 2025 | Oppenheimer | Assumes | Outperform | $15 |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | Oppenheimer | Reiterates | Outperform | — |
| 17 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Apr 2024 | Oppenheimer | Reiterates | Outperform | — |
| 17 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Apr 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
KALA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KALA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −345.3%
- Return on assets
- −65.4%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kala Bio, Inc. has a market value of $1.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$10.1M.
Free cash flow in the twelve months to 30 June 2026: −$19.9M.
Kala Bio, Inc. employs 6 people.
Data provided by Twelve Data
KALA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KALA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kala Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KALA
How does Ticker Nerd's model rank KALA?
As at 21 Nov 2026, Kala Bio, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (71 of 100).
What is the KALA stock forecast for 2030?
No analyst covering Kala Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KALA are extrapolating price history, which says nothing about the business.
What does Kala Bio, Inc. do?
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases affecting the front and back of the eye. Its primary development focus is KPI-012, an investigational biologic based on a mesenchymal stem cell secretome platform and designed to address persistent corneal epithelial defects, a condition involving impaired corneal healing.
About Kala Bio, Inc.
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases affecting the front and back of the eye. Its primary development focus is KPI-012, an investigational biologic based on a mesenchymal stem cell secretome platform and designed to address persistent corneal epithelial defects, a condition involving impaired corneal healing. The company’s activities center on ophthalmic research, clinical development, regulatory work, and potential commercialization of specialized treatments for patients with limited therapeutic options. KALA BIO, Inc. operates within the biotechnology and pharmaceutical sectors, with particular relevance to regenerative medicine, ocular surface disease, and rare-disease therapeutics. Its business model is centered on advancing proprietary product candidates through clinical development and establishing a specialized pipeline in ophthalmology. The company’s role in the financial market reflects the characteristics of a development-stage life sciences business, where value is closely connected to scientific research, clinical programs, intellectual property, and regulatory progress.
CEO Mr. Avi Minkowitz · 6 employees · United States · https://www.kalarx.com